Tema ETF Trust Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS) Dividend History

Company News

• EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'

  Novo Nordisk faces political pressure over high U.S. prices for its weight-loss drugs, Ozempic and Wegovy, ahead of the 2024 election. The company's CEO blamed pharmacy benefit managers (PBMs) for the high consumer costs, despite potential manufacturer price reductions.

  Benzinga
• ETFs to Profit from the Weight Loss Drug Boom

  The market for GLP-1 drugs could soar to $130 billion by 2030

  Zacks Investment Research

  Featured Companies: LLY NVDA OZEM THNR TSLA
• Play These New ETFs to Tap Lucrative Weight Loss Drug Market

  Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.

  Zacks Investment Research

  Featured Companies: LLY
• Healthcare ETFs for the Weight-Loss Drug Boom & Beyond

  We discuss attractive investment opportunities within the healthcare industry.

  Zacks Investment Research

  Featured Companies: CANC LLY RSHO
• Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only Growing

  David Song, PM of the Cardiovascular and Metabolic ETF (NASDAQ: HRTS) for Tema ETFs, was recently interviewed by Benzinga. Tema is an active investment adviser focused on differentiated strategies managed by experienced investment professionals offered through ETFs and SMAs. ...Full story available on Benzinga.com

  Benzinga